In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

according to a new poll from The Associated Press-NORC Center for Public Affairs Research. About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds When it ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the effects weight-loss drugs have had on their romantic relationships ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists currently prescribed for weight ... this new research does not demonstrate that Ozempic and similar drugs can help ...